#AbbVie

A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco

Nearly all those treated in a recent trial were cured.

The study population included those with all hepatitis C genotypes—except genotype 3.

A recent analysis of two studies of AbbVie’s hepatitis C regimen showed good results in this population.

The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.

Nearly all those who have recently completed treatment in an Italian cohort are apparently poised for a cure.

A recent study analyzed kidney parameters among those with HIV who were treated for hep C with the regimen.

A roundup of key findings from the Annual Meeting of the American Association for the Study of Liver Diseases in Washington, DC

The recently approved combination tablet includes the medications glecaprevir and pibrentasvir.

A pooled analysis of numerous studies found the safety and efficacy of the regimen was comparable between those under and those over 65.

The Food and Drug Administration has approved AbbVie’s once-daily Mavyret to treat all six major genotypes of hepatitis C virus (HCV).

The U.S. FDA approved hepatitis C treatment Mavyret, for all genotypes, for patients without cirrhosis and those with compensated cirrhosis.

Accessing new hepatitis C treatments is a problem for patients, even with drugs at reduced costs

The Food and Drug Administration (FDA) recently approved AbbVie’s Mavyret, the newest treatment for chronic hepatitis C.

The two-drug regimen can cure the virus in as little as eight weeks.